Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (Q87809056)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 January 2014

Language	Label	Description	Also known as
English	Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial	scientific article published on 24 January 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

type 2 diabetes

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Anthony H Barnett

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Ambrish Mithal

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jenny Manassie

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Russell Jones

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Henning Rattunde

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Hans J Woerle

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Uli C Broedl

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

EMPA-REG RENAL trial investigators

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

24 January 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

369-384

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Standards of medical care in diabetes--2012

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970208-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(13)70208-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795251%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87809056&oldid=1516071587"